Novo Nordisk experienced a significant stock decline following disappointing results from the ZEUS trial of its experimental heart drug Ziltivekimab on July 31. The Danish drugmaker’s shares fell approximately 7.5% in Copenhagen trading and dropped 8.6% in early U.S. trading after the company announced that the drug had failed to meet its primary objective.
The ZEUS trial enrolled more than 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and ongoing inflammation. Ziltivekimab, a once-monthly injection designed to block the IL-6 protein that drives inflammation, successfully reduced inflammation markers as intended. However, this biological effect did not translate into fewer major adverse cardiovascular events such as heart attacks, strokes, or cardiovascular deaths. The trial produced a hazard ratio of 0.99, indicating that patients receiving the drug faced nearly identical cardiovascular risk as those on placebo. Additionally, patients on Ziltivekimab experienced higher rates of serious infections compared to the placebo group, though overall mortality remained similar.
The trial failure represents a setback for Novo’s efforts throughout 2026 to demonstrate growth beyond its dominant weight-loss and diabetes franchises with Wegovy and Ozempic. Analysts had widely anticipated that Ziltivekimab would deliver at least some cardiovascular benefit and potentially generate billions in annual sales. The company indicated it will record a non-cash impairment charge in the third quarter of 2026 related to the trial failure, though this will not impact its adjusted operating profit outlook.
Novo retains two additional opportunities to salvage its cardiovascular strategy. The HERMES trial continues evaluating Ziltivekimab in patients with heart failure, while the ARTEMIS trial studies the drug in patients recovering from acute heart attacks. Both trials are expected to yield results in the first half of 2027. The company plans to present complete ZEUS data at a medical conference later in the year, potentially revealing whether specific patient subgroups benefited from the treatment. The setback arrives amid heightened competitive pressure from Eli Lilly in the weight-loss drug market and a pending shareholder lawsuit related to another failed trial program from 2024.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI